| 영문 | cardiotonic, cardiotonic agent | 한글 | 강심제 |
|---|---|---|---|
| 설명 | 심장의 수축력을 증감시키는 약물을 말한다. 기본적으로 심근수축력을 증강시켜 심장박출량을 증가시키는 약물이다. 강심배당체, 포스포디에스트라아제 억제제, 아드레날린 β수용체작용제, 혈관확장제 등이 있다. 대표적인 예로서는 디곡신(digoxine) 등의 디지탈리스(digitalis)가 있다. |
||
| 영문 | alkylating agent | 한글 | 알킬화약물 |
|---|---|---|---|
| 설명 | 항암제의 일종. 이상적인 항암제는 정상적인 세포에는 해를 주지 않고 단지 암세포에만 치명적인 효과를 나타내야 한다. 이렇게 하려면 암세포만의 특이한 특성을 이해하고 그곳에만 작용하는 약물을 개발해야 한다. 현재 대부분의 항암제는 암세포가 정상 세포에 비하여 월등히 증식을 빨리한다는 특성을 이용하고 있다. 증식이 빠르다는 것은 다시 말하면 유전 정보를 가지고 있는 DNA의 복제가 빠르다는 것을 의미한다. 만약 DNA의 복제를 방해한다면 증식이 아주 빠른 암세포에게는 치명적이지만 영원히 증식을 하지 않는 DNA의 복제가 거의 필요없는)신경세포나 증식이 암세포에 비해서 아주 느린 정상세포에는 거의 영향을 주지 못한다. 하지만 신체에서도 증식이 암세포와 비슷한 수준으로 일어나는 정상적인 세포가 있는데 그것은 머리카락을 만드는 모낭세포와 소화관의 점막을 이루는 세포와 혈액의 세포를 만드는 골수 세포이다. 그러므로 항암제를 사용할 경우 암세포와 마찬가지로 이들 세포도 함께 치명적인 영향을 입을 것은 당연하다(그래서 항암제 치료시엔 머리가 빠지고 소화불량이 잘 온다). 알칼화약물의 경우에는 DNA와 직접 결합을 하여 DNA의 복제를 억제함으로써 항암제의 역할을 수행한다. |
||
| 영문 | anti-inflammatory agent | 한글 | 항염증제, 소염제, 염증약 |
|---|---|---|---|
| 설명 | 국소에 작용하여 염증을 치료하고 방지하는 약. 염증을 가라앉히는 약을 말한다. 조직을 긴축-치밀하게 하여 장액과 점액의 분비를 줄이고, 표면에 있는 작은 혈관에 빈혈을 일으켜 충혈되는 것을 방지함으로써 염증적 병변을 제거하여 모든 증세를 없앤다. 대부분의 수렴제-완화제-진양제가 이에 속한다. 중요한 성분으로는 알루미늄-비스무트-아연-납화합물(병반-페르마톨-아연화-연당 등) 등이 있다. 작용에 따라 항염증진통제와 항염증효소제로 나뉜다. |
||
| NMB | neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ... |
|---|---|
| SBF | serologic-blocking factor; specific blocking factor; splanchnic blood flow |
| GBA | ganglionic blocking agent; gingivobuccoaxial |
| NMBA | neuromuscular blocking agent |
| SMCA | smooth muscle contracting agent; suckling mouse cataract agent |
| NMBA | Neuromuscular blocking agent |
|---|---|
| PIBF | Progesterone Induced Blocking Factor |
| TSBAb | Thyroid stimulation blocking antibodies |
| TSBAb | Thyroid stimulation-blocking antibody |
| BF | blocking factor |
| blocking agent | A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers." (05 Mar 2000) |
|---|
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
|---|---|
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| alpha-adrenergic blocking agent | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
| beta-adrenergic blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| ganglionic blocking agent | An agent that impairs the passage of impulses in autonomic ganglia. (05 Mar 2000) |
| slow channel-blocking agent | calcium channel-blocking agent |
| neuromuscular blocking agent | A group of drugs that prevent motor nerve endings from exciting skeletal muscle. They act either by competing for the neurotransmitter, acetylcholine, (like D-tubocurarine, mivacurium and pancuronium), or by first stimulating the postjunctional muscle membrane and subsequently desensitizing the muscle endplates to the acetylcholine (like succinylcholine or decamethonium); used in surgery to produce paralysis and facilitate manipulation of muscles. (05 Mar 2000) |
| nondepolarising neuromuscular blocking agent | A compound that paralyzes skeletal muscle primarily by inhibiting transmission of nerve impulses at the neuromuscular junction rather than by affecting the membrane potention of motor endplate or muscle fibres. (05 Mar 2000) |
| alpha blocking | The attenuation of the occipital alpha rhythm (8-14 Hz brain waves as seen on an electroencephalogram), produced by opening the eyes or by intense mental concentration. (05 Mar 2000) |
| antibodies, blocking | Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies. (12 Dec 1998) |
| blocking | 1. Obstructing; arresting of passage, conduction, or transmission. 2. In psychoanalysis, a sudden break in free association occurring when a painful subject or repressed complex is touched. 3. Sudden cessation of thoughts and speech, which may indicate the presence of a severe thought disorder or a psychosis. (05 Mar 2000) |
| blocking activity | The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus. (05 Mar 2000) |
| blocking antibody | An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor. See: desensitisation. (18 Nov 1997) |
| Rh blocking test | A test for nonagglutinating Rh antibodies: an Rh agglutination test is first carried out; if the test for Rh agglutinins is negative, then 1 drop of anti-Rho agglutinating serum of moderate titre is mixed with the patient's serum containing Rh-positive test cells; if after incubating for from 1 to 2 hr at 37캜 no agglutination occurs, Rho-blocking antibodies are assumed to be present in the patient's serum. (05 Mar 2000) |
| blocking agent |
blocker: a class of drugs that inhibit (block) some biological process
출처: wordnet.princeton.edu/perl/webwn
|
|---|---|
| blocking agent |
Isocyanates, normally extremely reactive with water, can only be used in waterborne coatings if they can be prevented from reacting before the water is baked out of the paint film. This is done by capping or blocking the isocyanate group with a thermally decomposable chemical. In a bake oven, the water evaporates, the chemical cap decomposes and the isocyanate crosslinks the paint. Blocked isocyanates are often employed for E-coat curing.
출처: www.etfinancial.com/coatingsgloss.htm
|
| blocking agent | a class of drugs that inhibit (block) some biological process |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|